Peter J. Mariani Purchases 20,000 Shares of Cytosorbents Co. (NASDAQ:CTSO) Stock

Cytosorbents Co. (NASDAQ:CTSO) CFO Peter J. Mariani acquired 20,000 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The stock was bought at an average price of $0.96 per share, with a total value of $19,200.00. Following the transaction, the chief financial officer now directly owns 401,363 shares in the company, valued at $385,308.48. The trade was a 5.24 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Cytosorbents Price Performance

Shares of CTSO stock opened at $0.81 on Wednesday. The firm’s 50 day moving average price is $0.97 and its two-hundred day moving average price is $1.02. The stock has a market cap of $44.30 million, a PE ratio of -2.25 and a beta of 0.57. Cytosorbents Co. has a 52-week low of $0.70 and a 52-week high of $2.15. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97.

Wall Street Analyst Weigh In

CTSO has been the subject of several research reports. HC Wainwright reissued a “neutral” rating and issued a $1.00 target price on shares of Cytosorbents in a research note on Monday, November 11th. StockNews.com initiated coverage on Cytosorbents in a report on Thursday, December 12th. They set a “hold” rating for the company.

Institutional Investors Weigh In On Cytosorbents

A number of institutional investors have recently made changes to their positions in CTSO. Sargent Investment Group LLC lifted its stake in Cytosorbents by 13.4% in the third quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock valued at $2,439,000 after buying an additional 192,747 shares during the period. CM Management LLC raised its position in shares of Cytosorbents by 3.0% in the 2nd quarter. CM Management LLC now owns 850,000 shares of the medical research company’s stock valued at $598,000 after acquiring an additional 25,000 shares during the period. Geode Capital Management LLC boosted its stake in Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after acquiring an additional 32,415 shares during the last quarter. Finally, Atomi Financial Group Inc. acquired a new position in Cytosorbents during the third quarter valued at approximately $51,000. 32.87% of the stock is owned by institutional investors and hedge funds.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.